Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brensocatib PK with Rifampin or Esomeprazole
NCT05826574Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brensocatib in Non-cystic fibrosis bronchiectasis (NCFB) (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Area Under the Concentration-time Curve. Started May 2023; status: completed.
02
Drugs
brensocatib
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT05826574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826574.